Join us at InCabin 2022 and hear from Dr Trefor Morgan, Optalert General Manager – Research and Development, who will be delivering a session on Measuring and Demystifying Drowsiness. Session Synopsis If done correctly, drowsiness can be quantified from its early stage through to the late stages. There is a biological based change that occurs...

Latest News Today, Melbourne based Medtech company, Optalert Australia, were announced as the recipient of the Australian Government – Automotive Innovation Lab Access Grant (AILAG).   The grant will be used to advance the development of the Optalert Video Automotive technology solution for the objective, early prediction of drowsiness and attentiveness monitoring. The project aims to...

The National Transport Commission (NTC) and the Cooperative Research Centre for Alertness, Safety and Productivity (Alertness CRC) today released the results of a world-first study into heavy vehicle driver fatigue. The two-year scientific study evaluated alertness monitoring technology and the impacts of work shifts on driver alertness. It analysed shift start time, the number of...

  BIO International Convention is back in Philadelphia, June 3-6, to celebrate the globally important innovations in biotech that start with one: one meeting, one theory, one trial, one breakthrough. Optalert look forward to joining the global biotech community during partnering sessions and will be available for meetings through the official Bio2019 partnering portal, opening...

Optalert is pleased to introduce the BlinQ system for the measurement of drowsiness or wakefulness in clinical trials. Optalert uses advanced patented algorithms to determine the exact drowsiness or wakefulness of a subject.  By applying Artificial Intelligence techniques and machine learning Optalert has been able to objectively quantify drowsiness or wakefulness.  Utilising the Johns Drowsiness Scale (JDS), Optalert’s future-proofed...

Pharmaceutical companies face many challenges, with hundreds of new drugs required to transition through clinical trial phases, regulatory processes and to market, more quickly and more efficiently. The Centre for the Study of Drug Development (CSDD) estimates the cost of developing a prescription drug that gains market approval at $2.6 billion. Even more remarkable is...